Skip to main content

Table 5 Clinical response measures

From: Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

 

Median day 0 (n = 30)

Median day 134 (n = 21)

Median improvement persistent responders (n = 16)

Median improvement transient/non-responders (n = 5)

Tender joint count

13

2

70%

44%

Swollen joint count

9

6

49%

40%

Patient global assessment

44.0

9.0

67%

25%

Patient pain

52.0

23.0

65%

9%

Physician global assessment

45.5

24.5

61%

20%